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SUMMARY. The effect of antisecretory treatment on extraesophageal symptoms of gastroesophageal reflux
disease was evaluated. Seventy-eight children presenting with typical and extraesophageal symptoms of gastro-
esophageal reflux disease underwent amultichannel intraluminal impedance and pHmonitoring (MII/pH). Children
with a positive MII/pH were randomly treated with proton pump inhibitors (PPIs) or histamine H2-receptor
antagonists (H2RAs) during 3 months. At the end of the treatment period, all patients were recalled. A second
treatment period of 3 months was given to those patients who were not symptom-free after 3 months. Thirty-five of
the forty-one (85.4%) children with a pathologic MII/pH presented with extraesophageal symptoms and were
treated with PPIs (omeprazole; n:19) or H2RAs (ranitidine; n:16) for 12 weeks. After 3 months, 11/19 (57.9%)
PPI-treated patients had a complete resolution of symptoms; 6/8 nonresponders were treated with PPI for another
3 months and became all symptom-free. The other two underwent a Nissen fundoplication. Only 5/16 (31.2 %)
patients treated with H2RAs had a complete resolution of symptoms after 3 months; 1/11 was treated again
with H2RAs during 3 months, and 10/11 were changed to PPIs. In 3/10, a partial resolution of symptoms was
achieved, while in 7/10, a complete remission was obtained (P < 0.05). Antisecretory reflux treatment improves
extraesophageal reflux symptoms. The efficacy of PPIs is superior to that of H2RAs in these children.
KEY WORDS: gastroesophageal reflux (disease), multichannel intraluminal impedance, pH monitoring,
proton pump inhibitor, respiratory symptom.
INTRODUCTION
Extraesophageal manifestations associated with gas-
troesophageal reflux disease (GERD) include res-
piratory conditions or symptoms such as asthma,
wheezing, bronchitis, pneumonia, bronchiectasis,
cough, apnea, apparent life-threatening events, condi-
tions affecting the ear, nose, and throat (ENT), such as
sinusitis, otitis media, and laryngotracheitis, and
dental erosion.1
The diagnostic yield of esophageal pH monitoring
in patients with respiratory symptoms is limited to
acid reflux, and its sensitivity is higher in erosive
than in nonerosive GERD.2 Sensitivity and specific-
ity is improved by using a combination of multi-
channel intraluminal impedance and pH monitoring
(MII/pH).3 Combined MII/pH detects acid, weakly
acid, and non-acid reflux episodes. MII/pH is supe-
rior to pH monitoring alone for the evaluation of
a temporal relation between symptoms and reflux
episodes.3,4
In children, proton pump inhibitors (PPIs) have
been shown to be effective and safe for short-term
treatment of erosive esophagitis and GERD symp-
toms that are refractory to other drugs.4,5 Studies in
adults and children have reported that in comparison
with H2-receptor antagonists (H2RAs), PPIs results in
higher and faster rates of healing of erosive esopha-
gitis compared with H2RAs.4,5 Adult patients with
extraesophageal manifestations, such as laryngo-
pharyngeal reflux, of GERD may require longer (4
months are considered better than 2 months) and
high-dose (twice daily) acid-suppressive therapy for
symptom control4,5 than those with esophageal symp-
toms. However, no evidence has emerged for the
optimal treatment of reflux-related extraesophageal
symptoms in children. The aim of this study was
to evaluate the effect of antisecretory treatment on
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extraesophageal symptoms of GERD diagnosed by
MII/pH in children.
METHODS
A prospective study was conducted during 1 year,
including 78 consecutive children (mean age  SD:
40.6  36.4 months; range: 1–181 months) referred to
the Gastrointestinal Endoscopy and Motility Unit of
the Department of Pediatrics, University of Naples
‘Federico II,’ Italy, with esophageal and extraesoph-
ageal symptoms. The diagnosis of GERD was based
on the impact of symptoms on the general well-being
of the children4 and the results of the MII/pH.
Criteria for exclusion were esophageal abnormali-
ties caused by general or systemic disease, previous
esophageal and/or gastric surgery, and the presence of
esophageal stenosis, renal, cardiac, hepatic, or severe
chronic pulmonary diseases such as cystic fibrosis,
organ transplantation, central nervous systemdisease,
known food allergy, or celiac disease.
At enrollment, all patients underwent a clinical
evaluation. Esophageal and extraesophageal symp-
toms were recorded with a validated questionnaire by
one caregiver (DU) in order to obtain baseline data
on symptom severity and frequency.6 The severity of
symptoms was classified as follows: grade 0, no symp-
toms; grade 1, mild symptoms with spontaneous
remission and no interference with normal activity or
sleep; grade 2, moderate symptoms with spontaneous
but slow remission and mild interference with normal
activity or sleep; and grade 3, severe symptoms
without spontaneous remission and marked interfer-
ence with normal activity or sleep.6
The frequency of symptoms was classified as
follows: grade 0, absent; grade 1, occasional (symp-
toms present less than 2 days a week); grade 2, fre-
quent (symptoms present 2–4 days a week); and grade
3, very frequent (symptoms present more than 4 days
a week).6 A score for each symptom and a total
symptom score were calculated. The score for each
symptom was calculated by multiplying the severity
grade by the frequency grade, with a possible range
for each score of 0–9 (Table 1).
Combined MII/pH was performed in all patients.
Acid suppression therapy was discontinued 2 weeks
before testing, if applicable. A 2.1-mm diameter
MII/pH catheter with six impedance channels and
two (esophageal and gastric) antimony pH sensors
with external reference were used. Prior to the pro-
cedure, the pH sensor was calibrated using buffered
solutions of pH 4.0 and 7.0, as specified by the manu-
facturer (Sandhill Scientific, Inc., Highland Ranch,
CO, USA). The probe was then inserted through the
nose into the stomach, and the esophageal pH sensor
was positioned 5 cm above the LES, based on the
Strobel formula (length from nares to LES in
cm = 5 + 0.252[height]7,8). The six impedance chan-
nels were located 3, 4.5, 6, 7.5, 9, and 10.5 cm from
the distal tip for the infantile MII/PH probe for
infants younger than 1 year, and 3, 5, 7, 9, 11, and
13 cm from the distal tip for the pediatric MII/PH
probe for children older than 1 year. The catheter
was connected to a data logger (Sleuth System,
Sandhill Scientific, Inc.) that stores data from all
impedance channels with a frequency of 50 Hz. Acid
beverages were not allowed during registration.
Parents filled in a diary recording times of meals,
body position, and any symptom suggesting gas-
troesophageal reflux (GER) occurrence during the
recording period.
MII/pH tracings were evaluated using the
BioVIEW analysis software (Sandhill Scientific, Inc.)
and each study was manually reviewed. The follow-
ing parameters were analyzed: number of reflux epi-
sodes according to pH-metry and impedance criteria,
total duration of acid GER, reflux index (RI), and
bolus exposure index (BEI). Gas reflux, liquid reflux,
and mixed (combined gas and liquid) were deter-
mined byMII and analyzed through manual read out
by the same operator. All reflux events were catego-
rized as acid or non-acid, as determined by the pH
sensor, with acid <4 and non-acid >4. BEI was calcu-
lated as the total percentage of time with retrograde
movement of intraluminal esophageal material.
The lack of pediatric normal values for impedance
did not allow the determination of a clear-cut imped-
ance threshold. The analysis of the pH-metry was
considered abnormal if the RI was >10% in infants
and more than or equal to 5% in children.9 However,
because a BEI >1.4% has been proposed as an upper
limit (95th percentile) of normal impedance in
adults,10 this cut-off was also used in the analysis of
our results.11 In addition, to increase the accuracy of
the techniques, we have evaluated the symptom index
(SI) and the symptom association probability (SAP).
The SI ([number of reflux-associated symptoms/total
number of symptoms during 24 hours]/100) and the
SAP index was evaluated automatically by the soft-
ware, evaluating the relation between reflux epi-
sodes and symptoms through the Fisher formula.
A SI of >50 % and a SAP >95 % were defined as
pathologic.12,13
Patients with pathologic MII/pH were randomly
treated with a PPI (omeprazole, 1.4 mg/kg/day) or
H2RA (ranitidine, 15 mg/kg/day) during 3 months
and referred to their treating general pediatricians.
The caregivers of each child were contacted with a
telephone call at the end of the 3-month treatment. At
follow-up, the questionnaire was replicated for the
symptom score to evaluate the response to treatment
and clinical outcome. The patients were considered
to be healed when there was a complete remission
of the symptoms (score 0). If the children were not
symptom-free, a second treatment period of 3 months
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was started after which the parents were contacted
again.
Informed consent for participation in this study
was obtained from the parents of all patients, and the
experimental design was approved by the Indepen-
dent Ethics Committee of University of Naples
‘Federico II’. Given the fact that patients were symp-
tomatic, the Ethical Committee refused the inclusion
of a placebo group. All data were statistically ana-
lyzed with the SPSS version 8.0 program (SPSS, Inc.,
Chicago, IL, USA). Statistical tests used were the c2
test and Fisher’s exact test, depending on the number
of observations.
RESULTS
Forty-one of the 78 children (52.6%) had a pathologic
MII/pH. Thirty-five (mean age  SD: 40.6  36.4
months; range: 1–181 months) out of 41 (85.4%) pre-
sented with both esophageal and extraesophageal
symptoms of GERD. Of these 35 children, 19 (54.3%)
were treatedwith PPIs (1.4 mg/kg/day) and 16 (45.7%)
with H2RAs (15 mg/kg/day) for 12 weeks (Fig. 1,
Table 2). At baseline, both groups were comparable
for demographic data and severity of symptom scores.
Furthermore, the MII/pH parameters were compa-
rable in the two groups (Table 3). SAP index was
positive in eight (42.1%) patients in the group treated
with PPIs and in five (31.3%) patients in the group
treated with H2RA (P = 0.38). Also, the SI was not
statistically different.
Eleven children of the 19 (57.9%) treated with the
first cycle of PPI therapy had a complete resolution
of the symptoms, while in only five of the 16 children
(31.2%) treated with H2RA during the first cycle,
symptoms disappeared (odds ratio [OR] = 3.025;
P = 0.21). Regarding the first 3 months of treatment
(first cycle of treatment), PPI induce an absolute risk
reduction of 0.26 in comparison with H2RAs,
meaning that the outcome in the PPI group was
26% better than in the H2RA group. The relative risk
reduction is 38.2%. The ‘number needed to treat’ is
3.8, meaning that for every 3.8 patients treated with
Table 1 Distribution of the score in the study population
Symptom Score PPI, 19 patients H2RA, 16 patients
BT AT BT AT
Patient % Patient % Patient % Patient %
Vomiting 1 8 42.1 4 21 4 25 1 6.2
2 2 10.5 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0
4 2 10.5 0 0 1 6.2 0 0
6 0 0 0 0 0 0 0 0
9 2 10.5 0 0 4 25 3 18.7
Chest pain 1 4 21 1 5.3 0 0 0 0
2 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0
9 1 5.3 0 0 1 6.2 1 6.2
Irritability 1 3 15.8 1 5.3 0 0 0 0
2 0 0 0 0 1 6.2 0 0
3 0 0 0 0 0 0 0 0
4 1 5.3 0 0 1 6.2 1 6.2
6 0 0 0 0 1 6.2 0 0
9 1 5.3 0 0 0 0 0 0
Difficulty
swallowing
1 3 15.8 0 0 1 6.2 0 0
2 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0
6 0 0 0 0 1 6.2 1 6.2
9 0 0 0 0 1 6.2 1 6.2
Cough 1 3 15.8 0 0 1 6.2 2 12.5
2 5 26.3 1 5.3 6 37.5 0 0
3 6 31.6 1 5.3 4 25 3 18.7
4 3 15.8 0 0 5 31.2 4 25
5 0 0 0 0 0 0 0 0
Other respiratory
symptoms, such
as wheezing
1 2 10.5 0 0 3 18.7 2 12.5
2 0 0 0 0 1 6.2 1 6.2
3 1 5.3 0 0 1 6.2 0 0
4 1 5.3 0 0 2 12.5 0 0
6 8 42.1 1 5.3 0 0 0 0
9 6 31.6 1 5.3 8 50 4 25
AT, after treatment; BT, before treatment; H2RA, H2-receptor antagonist; PPI, proton pump inhibitor.
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PPIs, there is one more symptom-free compared with
the H2RA group. The symptom score after the first 3
months of treatment was significantly lower
(P < 0.001) in the children treated with PPIs com-
pared with those treated with H2RA (Table 4).
Six of the 8 children (31.6%) who showed an
improvement but not a resolution of symptoms after
3 months of PPI treatment had another cycle of 3
months during which the same therapy was adminis-
tered. They became all symptom-free after the second
treatment period of 3 months. A Nissen fundoplica-
tion was performed in both patients in whom symp-
toms persisted despite 6 months PPI therapy (10.5%);
endoscopy did not reveal hiatal hernia in these
patients.
Ten of the 11 patients (90.9%) in whom symptoms
persisted after treatmentwithH2RAswere switched to
PPIs during 3 months. In three of these 10 children
(30%), a partial resolution of symptomswas obtained.
The remaining seven children became symptom-free.
One patient of this group, who had an improvement
but not a resolution of symptoms, had another cycle of
H2RA therapy with a complete resolution.
Overall, 35 PPI 3-month treatments were pre-
scribed in 29 patients. In 24/29 (83%) patients, this
was related to a complete resolution of symptoms. Of
the 17 H2RA treatments, only six (35.3%) had a com-
plete resolution of symptoms (OR 8.8; P = 0.03). No
adverse events of the treatment were reported.
DISCUSSION
The efficacy of antisecretory treatment in children
with extraesophageal symptoms was evaluated in this
Fig. 1 Diagram of the included patients.
Table 2 Clinical characteristics of the study population at
inclusion
PPI group H2RA group
N (patients) 19 16
Age (mean  1 SD) 46.4  42.5 34.5  28.8months
Vomiting 14 9
Chest pain 5 1
Irritability 5 3
Dysphagia 3 3
Cough 17 16
Respiratory symptoms
Apnea 6 4
Bronchospasm 1 0
Asthma 5 3
Laryngospasm 5 5
Pneumonia 5 1
Hoarseness 1 1
None of the parameters was statistically significant. H2RA,
H2-receptor antagonist; PPI, proton pump inhibitor; SD, standard
deviation.
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study, and PPIs were shown to be more effective than
H2RAs. Three months of treatment was too short in
some of these patients, because resolution was only
achieved after 6 months in a subgroup. PPIs are
known to be better than H2RAs in the treatment of
esophageal symptoms and esophagitis;14 our results
suggest that PPI are more effective in the treatment of
extraesophageal symptoms caused by GER.
It is well known that a variety of extraesophageal
symptoms, such as respiratory, and ENT symptoms
and disorders, may be manifestations of GERD.15,16
Symptoms may result from macroaspiration and
microaspiration of refluxed gastroduodenal contents
causing a direct deleterious effect of gastric juice on
the mucosa of the tracheobronchial tree, the laryn-
gopharynx – including vocal cords – the middle ear,
and the nasosinusal complex.15,16 The common vagal
nerve innervation of the esophagus and the pulmo-
nary tree may result in reflex-mediated reaction trig-
gering extraesophageal symptoms via neuronal
esophageal-pulmonary tree reflex.9,17
Compared with the H2RAs, PPIs have been
reported to have a greater inhibitory effect on gastric
acid production. A meta-analysis comparing rates of
healing of esophagitis demonstrated that omeprazole
had a therapeutic advantage of 35–40% over H2RAs.5
The duration of PPI treatment needed to result in
healing of esophagitis has been suggested to range
between 8 and 12 weeks.18 In adults, it has been dem-
onstrated that effectiveness is directly related to the
degree and duration of acid inhibition, and the
healing rates for reflux esophagitis appear to be
similar for all PPIs.19 Although PPI therapy provides
rapid symptomatic relief and healing of esophagitis,
extraesophageal symptoms improve slowly and may
require higher doses of PPIs.20
On the other hand, the effect of PPIs on extra-
esophageal or atypical manifestations of GERD
remains unclear. Several studies evaluated the effi-
cacy of antisecretory treatment on atypical symptoms
of GERD and showed conflicting results.2,21,22 In
adults, several studies evaluating the efficacy of PPI
therapy on chronic cough had negative results. A
review of different studies comparing PPI treatment
with placebo in patients with respiratory symptoms
did not find significant differences.2 These results are
confirmed in a large randomized controlled trial con-
ducted in patients with laryngeal reflux and ENT
manifestations, which failed to show any benefit of
40-mg esomeprazole during 16 weeks compared with
placebo 22. Weakly acid reflux episodes have been
demonstrated in adults to be more frequently associ-
ated with extraesophageal reflux symptoms such as
cough.21 A limited number of studies in children have
evaluated the effect of treatment on atypical reflux
symptoms. Khoshoo and Haydel enrolled 46 children
Table 3 Multichannel intraluminal impedance and pH monitoring values in both groups with percentage of abnormal results (at
inclusion)
PPI group H2RA group P
Mean  SD % abnormal Mean  SD % abnormal
Total n° reflux 56.5  38.9 45.8  41.3 0.23
Time pH < 4.0 75.1  125.8 69  115.7 0.44
Reflux index 9.9  9.9 42.1 6.1  9.3 37.5 0.47
BEI 49.6  39.9 52.6 30.2  25.2 68.7 0.06
Acid reflux 52.9  40.6 44.6  40.9 0.28
Weakly acid reflux 14.2  9.1 10.3  8.2 0.11
Non acid reflux 18.9  20.9 9.3  9.4 0.06
Symptom index 46.5  24.81 47.3 45.3  34.9 50 0.45
SAP 72.7  33.5 36.8 64.3  42.1 43.7 0.26
% abnormal is the % of patients in whom this parameter was abnormal. BEI, bolus exposure index; H2RA, H2-receptor antagonist;
PPI, proton pump inhibitor; SAP, symptom association probability; SD, standard deviation.
Table 4 Symptom score (mean  1 SD) before and after the first cycle of therapy
PPI (n = 19) H2RA (n = 16) P
BT AT BT AT
Vomiting 2.26  1.24 0.21  3.9 2.75  3.86 1.75  3.61 0.0003
Chest pain 0.68  2.06 0.05  0.23 0.56  2.25 0.56  2.25 0.01
Irritability 0.84  2.19 0.16  0.69 0.81  1.77 0.25  1 0.6
Difficulty swallowing 0.16  0.37 0  0 1  2.61 0.94  2.62 0.2
Cough 2  2.73 0.26  0.81 2.81  0.98 1.69  1.78 0.0001
Respiratory symptoms 5.84  2.91 0.79  2.42 5.5  3.76 2.5  3.92 0.000001
The P value indicates the difference between PPI and H2RA group after therapy. AT, after therapy; BT, before therapy; H2RA, H2-receptor
antagonist; PPI, proton pump inhibitor.
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with nonatopic persistent asthma despite broncho-
dilators, inhaled corticosteroids, and leukotriene
antagonists. A pH-metry was abnormal in 27/46
(59%). Anti-GER treatment (PPI and metoclopra-
mide) in patients with ‘GERD and asthma’ resulted
in a significant reduction in asthma medication. In a
subgroup of eight patients with a normal pH-metry,
the same treatment resulted in a reduction of asthma
medication in two of the eight (25%), while there was
no reduction in control patients.21 Stordal et al. per-
formed the first and so far only methodologically
sound, randomized, double-blind, placebo-controlled
clinical trial analyzing the efficacy of a PPI (omepra-
zole) in pediatric patients with asthma and GERD.
Omeprazole treatment did not improve asthma
symptoms in children with asthma and GERD.19
A more recent study in adults showed that extra-
esophageal symptoms are frequent in patients with
classic GERD and that PPI therapy is likely to
improve or resolve the symptoms.23 In our study,
treatment with PPI showed a higher efficacy than
H2RA, although the difference did not reach a statis-
tical significant difference. But, after the second cycle,
PPIs showed a significant higher efficacy than that
of H2RAs. Differently from experience in adults,
according to our data, we can hypothesize that acid
reflux and not only weakly acid reflux may cause
atypical GERD. This could explain the high efficacy
of PPIs on atypical symptoms in children. In addi-
tion, our population shows a higher percentage of
acid reflux in the impedance analysis compared with
other studies in literature. This may be influenced
by the use of the Strobel formula for placing of the
probe. Other studies in literature show a larger per-
centage of weakly acid and alkaline reflux. In these
studies, the location of the probe was determined
with a radiographic control.24,25
Wunderlich and Murray first used SAP analysis to
determine the temporal relationship between cough
and acid reflux events, and found that 35% of patients
had a positive SAP.26,27 In our population, SAP was
positive in 37% of the children in both treatment
groups, while SI was positive in 50% of patients. This
result is comparable with those found in literature.28
During treatment, no side effects were reported by
the parents. The limits of our study include the open
comparative design, the lack of a placebo-controlled
group, as well as the lack of a repeated MII/pH
during follow-up. However, response to treatment is
clinically more relevant than improvement ofMII/pH
parameters. Moreover, parents of children who were
asymptomatic would most likely not have permitted a
second MII/PH to be performed.
In conclusion, the improvement of extraesophageal
symptoms in children with GERD in response to PPI
therapy suggests a possible cause–effect relation. The
efficacy of PPIs in the treatment of extraesophageal
reflux symptoms suggests the possibility of using these
drugs as a better option than H2RAs, as already
approved for erosive esophagitis and relief of GERD
typical symptoms. However, because the number of
children in our study is small, more data are needed
before firm recommendations can be made. Interest-
ing, only two children (5.7 %) underwent a Nissen
fundoplication. Larger randomized controlled trials
with a structured long-term follow-up are needed to
confirm our results.
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